Another study on colorectal cancer reported evidence that SIT could activate p53 by disrupting p53-MDM2 (an E3 ubiquitin ligase inducing p53 ubiquitination and degradation) interaction, leading to increased translocation of p53 to the nucleus and silencing of the NF-κB pathway, which is essential for BCRP expression. Here, TP53 is linked to colorectal cancer.